Bruce Broad | Clinical Professor of Dermatology at Perelman School of Medicine
University of Pennsylvania

Bruce Broad, Clinical Professor of Dermatology at Perelman School of Medicine, University of Pennsylvania

Dr. Brod received his medical degree from the University of Pennsylvania and completed his residency in Dermatology at the University of Pittsburgh after completing a one-year internship in Internal Medicine at Brown University. He was Board certified in Dermatology in 1991 and recertified in 2009. A Fellow of the American Academy of Dermatology, Dr. Brod is a Clinical Professor of Dermatology at the University of Pennsylvania School of Medicine where he teaches and is the Director of the Contact Dermatitis Clinic.
Dr. Brod is currently on the Board of Directors of the Pennsylvania Academy of Dermatology and Dermatologic Surgery and the Immediate Past President of the American Contact Dermatitis Society. He is the Chair of the AAD/A Congressional Policy Committee and immediate past chair of the AAD/A Drug Pricing and Transparency Task Force where he still serves as a member. Dr. Brod has lectured at state and national meetings on Drug Pricing in Dermatology and has co-authored a recent article on generic drug pricing soon to be published in the Journal of Investigative Dermatology. He is on active staff at the Hospital of the University of Pennsylvania and Children’s Hospital of Philadelphia

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 11:30

PANEL: Transparency across the drug supply chain- how can we get costs out in the open?

  • Pharmaceuticals originate in manufacturing sites; are transferred to wholesale distributors; stocked at retail, mail-order, and other types of pharmacies; subject to price negotiations and processed through quality and utilization management screens by pharmacy benefit management companies (PBMs); dispensed by pharmacies; and ultimately delivered to and taken by patients
  • How to deliver the best value to patients and those that are exposed to vulnerability from high prices
  • What each player does and the role that it plays in the flow of pharmaceuticals from manufacturer to patient
  • How cash flow works between the manufacturer and the patient
  • What would be the impact of greater transparency?

back to speakers